Interim analysis from a phase 1a clinical trial reveals that IMA401, a bispecific T cell engager, generated preliminary efficacy signals in patients with recurrent and refractory head and neck cancers and melanoma. These cancers express MAGE-A4 and MAGE-A8 at notably high frequencies—up to 75 percent in melanoma and 65 percent in head and neck cancers—making them optimal candidates for antigen-targeted immunotherapy.
The trial data, presented at the 2026 ASCO Annual Meeting, documented a favorable safety profile alongside these early response indicators. IMA401 works by redirecting T cells to recognize cancer-specific antigens displayed on tumor cell surfaces, a mechanism distinct from traditional immunotherapies. The combination strategy with anti-PD-1 checkpoint inhibitors demonstrated enhanced immune activation potential, suggesting a complementary approach for overcoming resistance mechanisms.
These results warrant further investigation in expanded patient cohorts. Read the full article on GMJ Newsroom.
Was this article helpful?
